Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of “Moderate Buy” from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $25.4444.

ARCT has been the subject of several research reports. Citigroup decreased their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. B. Riley Financial initiated coverage on shares of Arcturus Therapeutics in a research note on Wednesday, March 18th. They set a “buy” rating and a $22.00 price objective for the company. Piper Sandler decreased their price objective on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Finally, Weiss Ratings upgraded shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st.

Arcturus Therapeutics Stock Performance

ARCT stock opened at $7.30 on Wednesday. The stock has a 50-day moving average price of $8.04 and a two-hundred day moving average price of $7.41. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The company has a market cap of $207.47 million, a PE ratio of -2.60 and a beta of 2.36.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The firm had revenue of $2.06 million during the quarter, compared to the consensus estimate of $6.30 million. Equities analysts forecast that Arcturus Therapeutics will post -3.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. boosted its stake in shares of Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA purchased a new position in shares of Arcturus Therapeutics in the third quarter valued at $111,000. CANADA LIFE ASSURANCE Co boosted its stake in shares of Arcturus Therapeutics by 27.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,567 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Arcturus Therapeutics by 42.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 2,313 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.